Ceftriaxone: clinical review, consumption in Portugal and safety alerts

Ceftriaxone is a 3rd generation cephalosporin, often prescribed because of its broad spectrum of action. Objectives: (i) To prepare a clinical review of ceftriaxone. (ii) To describe/analyse the profile of cephalosporins consumed in outpatient clinics by Portuguese districts in 2015. (iii) To identi...

Full description

Bibliographic Details
Main Authors: Carla Pires, Ana Fernandes
Format: Article
Language:English
Published: ALIES - Associação Lusófona para o Desenvolvimento da Investigação e do Ensino das Ciências da Saúde 2018-12-01
Series:Journal Biomedical and Biopharmaceutical Research (BBR)
Subjects:
Online Access:http://www.alies.pt/BBR%20Editions/Vol-15-2-2018/art9.pdf
id doaj-6c5b5a5cde7d473bb18733e20e49c856
record_format Article
spelling doaj-6c5b5a5cde7d473bb18733e20e49c8562020-11-24T21:47:07ZengALIES - Associação Lusófona para o Desenvolvimento da Investigação e do Ensino das Ciências da SaúdeJournal Biomedical and Biopharmaceutical Research (BBR) 2182-23602182-23792018-12-0115222424210.19277/bbr.15.2.189Ceftriaxone: clinical review, consumption in Portugal and safety alertsCarla Pires0Ana Fernandes1CBIOS - Universidade Lusófona's Research Center for Biosciences and Health TechnologiesCBIOS - Universidade Lusófona's Research Center for Biosciences and Health TechnologiesCeftriaxone is a 3rd generation cephalosporin, often prescribed because of its broad spectrum of action. Objectives: (i) To prepare a clinical review of ceftriaxone. (ii) To describe/analyse the profile of cephalosporins consumed in outpatient clinics by Portuguese districts in 2015. (iii) To identify/analyse the safety alerts of ceftriaxone issued by the National and European Medicines (EMA) Agencies. Methods: Diverse sources were accessed, namely PubMed and Micromedex. The report of INFARMED, I.P. on the consumption of cephalosporins in Portugal and the safety alerts of ceftriaxone on the website of INFARMED, I.P. and the EMA were consulted. Results: The clinical review was developed. The districts of Lisbon, Coimbra, Portalegre, Porto and Leiria presented consumptions above the national average (21.25 DHD). Ceftriaxone was the second most commonly used cephalosporin in this group. Only two informative circulars of INFARMED, I.P. on the safety of ceftriaxone were identified. Both circulars were based on the benefit risk assessments of EMA. Conclusion: The efficacy and safety profile of ceftriaxone remains favourable. It is possible that this antibiotic may be prescribed outside the scope of its therapeutic indications, considering the significant differences in its consumption among some Portuguese districts. Thus, monitoring for the appearance of bacterial resistance is critical.http://www.alies.pt/BBR%20Editions/Vol-15-2-2018/art9.pdfeftriaxone3rd generation cephalosporinantibiotic consumptionsafety alertspharmacovigilance
collection DOAJ
language English
format Article
sources DOAJ
author Carla Pires
Ana Fernandes
spellingShingle Carla Pires
Ana Fernandes
Ceftriaxone: clinical review, consumption in Portugal and safety alerts
Journal Biomedical and Biopharmaceutical Research (BBR)
eftriaxone
3rd generation cephalosporin
antibiotic consumption
safety alerts
pharmacovigilance
author_facet Carla Pires
Ana Fernandes
author_sort Carla Pires
title Ceftriaxone: clinical review, consumption in Portugal and safety alerts
title_short Ceftriaxone: clinical review, consumption in Portugal and safety alerts
title_full Ceftriaxone: clinical review, consumption in Portugal and safety alerts
title_fullStr Ceftriaxone: clinical review, consumption in Portugal and safety alerts
title_full_unstemmed Ceftriaxone: clinical review, consumption in Portugal and safety alerts
title_sort ceftriaxone: clinical review, consumption in portugal and safety alerts
publisher ALIES - Associação Lusófona para o Desenvolvimento da Investigação e do Ensino das Ciências da Saúde
series Journal Biomedical and Biopharmaceutical Research (BBR)
issn 2182-2360
2182-2379
publishDate 2018-12-01
description Ceftriaxone is a 3rd generation cephalosporin, often prescribed because of its broad spectrum of action. Objectives: (i) To prepare a clinical review of ceftriaxone. (ii) To describe/analyse the profile of cephalosporins consumed in outpatient clinics by Portuguese districts in 2015. (iii) To identify/analyse the safety alerts of ceftriaxone issued by the National and European Medicines (EMA) Agencies. Methods: Diverse sources were accessed, namely PubMed and Micromedex. The report of INFARMED, I.P. on the consumption of cephalosporins in Portugal and the safety alerts of ceftriaxone on the website of INFARMED, I.P. and the EMA were consulted. Results: The clinical review was developed. The districts of Lisbon, Coimbra, Portalegre, Porto and Leiria presented consumptions above the national average (21.25 DHD). Ceftriaxone was the second most commonly used cephalosporin in this group. Only two informative circulars of INFARMED, I.P. on the safety of ceftriaxone were identified. Both circulars were based on the benefit risk assessments of EMA. Conclusion: The efficacy and safety profile of ceftriaxone remains favourable. It is possible that this antibiotic may be prescribed outside the scope of its therapeutic indications, considering the significant differences in its consumption among some Portuguese districts. Thus, monitoring for the appearance of bacterial resistance is critical.
topic eftriaxone
3rd generation cephalosporin
antibiotic consumption
safety alerts
pharmacovigilance
url http://www.alies.pt/BBR%20Editions/Vol-15-2-2018/art9.pdf
work_keys_str_mv AT carlapires ceftriaxoneclinicalreviewconsumptioninportugalandsafetyalerts
AT anafernandes ceftriaxoneclinicalreviewconsumptioninportugalandsafetyalerts
_version_ 1725899252198014976